Listed

Integer Holdings Corp: Form 10-Q for the period ended Jul 2, 2021

Filed with the SEC on Jul 29, 2021 and accepted by EDGAR at Jul 29, 2021, 16:10 ET.

Share

Management's discussion and analysis

As filed, 46,943 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

This Quarterly Report on Form 10-Q should be read in conjunction with the disclosures included in our Annual Report on Form 10-K for the year ended December 31, 2020. In addition, please read this section in conjunction with our Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements contained herein.

Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:

  • the impact of the COVID-19 global pandemic;
  • future development and expected growth of our business and industry;
  • our ability to execute our business model and our business strategy;
  • having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and
  • projected capital spending.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “projects” or “continue” or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors and other risks and uncertainties that arise from time to time are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in other periodic filings with the Securities and Exchange Commission and include the following:

  • the impact of the COVID-19 global pandemic;
  • our dependence upon a limited number of customers;
  • pricing pressures that we face from customers;
  • our reliance on third party suppliers for raw materials, key products and subcomponents;
  • the potential for harm to our reputation caused by quality problems related to our products;
  • the dependence of our energy market-related revenues on the conditions in the oil and natural gas industry;
  • interruptions in our manufacturing operations;
  • our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures;
  • our ability to attract, train and retain a sufficient number of qualified associates;
  • our dependence upon our senior management team and technical personnel;
  • the intense competition we face and our ability to successfully market our products;
  • our ability to respond to changes in technology;
  • our ability to develop new products and expand into new geographic and product markets;
  • our ability to successfully identify, make and integrate acquisitions to expand and develop our businesses in accordance with expectations;
  • our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under our senior secured credit facilities;
  • economic and credit market uncertainties that could interrupt our access to capital markets, borrowings or financial transactions;
  • market and financial risks related to our international operations and sales;
  • our complex international tax profile;
  • our ability to realize the full value of our intangible assets
  • regulatory issues resulting from products complaints, recalls or regulatory audits;
  • the potential of becoming subject to product liability or intellectual property claims;
  • our ability to protect our intellectual property and proprietary rights;
  • our ability and the cost to comply with environmental regulations;
  • our ability to comply with customer-driven policies and third-party standards or certification requirements;
  • our ability to obtain necessary licenses for new technologies;
  • legal and regulatory risks from our international operations; and

- 25 -

  • the fact that the healthcare industry is highly regulated and subject to various regulatory changes.

Except as required by applicable law, the Company assumes no obligation to update forward-looking statements in this report whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

In this Form 10-Q, references to “Integer,” “we,” “us,” “our” and the “Company” mean Integer Holdings Corporation and its subsidiaries, unless the context indicates otherwise.

Our Business

Integer Holdings Corporation is one of the largest medical device outsource (“MDO”) manufacturers in the world serving the cardiac, neuromodulation, vascular, orthopedics, advanced surgical and portable medical markets. We also develop batteries for high-end niche applications in the non-medical energy, military, and environmental markets. Our vision is to enhance the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

We organize our business into two reportable segments, Medical and Non-Medical, and derive our revenues from four principal product lines. The Medical segment includes the Cardio & Vascular, Cardiac & Neuromodulation and Advanced Surgical, Orthopedics & Portable Medical product lines and the Non-Medical segment comprises the Electrochem product line. For more information on our segments, please refer to Note 14 “Segment Information” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report.

The second quarter and first six months of 2021 ended on July 2 and consisted of 92 days and 183 days, respectively. The second quarter and first six months of 2020 ended on July 3 and consisted of 91 days and 185 days, respectively.

Impact of COVID-19

Beginning in early March 2020, the global spread of the novel coronavirus (“COVID-19”) has created significant uncertainty and worldwide economic disruption. Specific impacts to our business include labor shortages, disruptions in the supply chain, delayed or reduced customer orders and sales, restrictions on associates’ ability to travel or work, and delays in shipments to and from certain countries. The extent to which COVID-19 will continue to impact our operations will depend on future developments, which remain highly uncertain and difficult to predict, including, among others, the duration of the outbreak, the effectiveness and utilization of vaccines for COVID-19 and its variants, new information that may emerge concerning the severity of COVID-19 and the actions, especially those taken by governmental authorities to contain the pandemic or treat its impact. As pandemic-related events continue to evolve, additional impacts may arise that we are not aware of currently. Any prolonged material disruption of our labor force, suppliers, manufacturing, or customers could materially impact our consolidated financial position, results of operations or cash flows.

Recent Business Acquisition

On February 19, 2020, we acquired certain assets and liabilities of InoMec Ltd. (“InoMec”), a privately-held company based in Israel that specializes in the research, development and manufacturing of medical devices, including minimally invasive tools, delivery systems, tubing and catheters, surgery tools, drug-device combination, laser combined devices, and tooling and production. The acquisition enables us to create a research and development center in Israel, closer to the customer base in the region.

Refer to Note 2 “Business Acquisition” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about this acquisition.

- 26 -

Strategic Overview

We continue to take steps to better align our resources in order to invest to grow and protect, and preserve our portfolio of products. In addition to our portfolio strategy, we continue to execute our six key operational strategic imperatives designed to drive excellence in everything we do:

  • Sales Force Excellence: We are focusing our efforts within the commercial organization to further improve our efficiency and effectiveness and to align with product line growth strategies and customer needs. These activities are about getting more out of the capabilities we already have, and increasing individual accountability and clarity of ownership, while serving customers more effectively.
  • Market Focused Innovation: We are ensuring we get the most return on our research and development investments. We are focused on having a clear picture of how we spend our money so we can increase investments to drive future growth.
  • Manufacturing Excellence: The goal is to deliver world-class operational performance in the areas of safety, quality, delivery and overall efficiency. We want to transition our manufacturing into a competitive advantage through a single, enterprise-wide manufacturing structure known as the Integer Production System. This system will provide standardized systems and processes by leveraging best practices and applying them across all of our global sites.
  • Business Process Excellence: We are taking a systematic approach to driving excellence in everything we do by standardizing, optimizing and ultimately sustaining all of our processes.
  • Leadership Capability: We have a robust plan to make leadership a competitive advantage for us, and as the success rate is higher with internal hires, we are focusing on finding and developing leaders from within the Company to build critical capabilities for future success.
  • Performance Excellence: We are raising the bar on associate performance to maximize our impact. This includes aligning key roles with critical capabilities, positioning the best talent against the biggest work, and putting tools and processes in place to provide higher financial rewards for top performers, so our top performers can see increased results in pay for increased results in their performance.

We believe we are well-positioned within the medical technology and MDO manufacturing market and that there is a robust pipeline of opportunities to pursue. We have expanded our medical device capabilities and are excited about opportunities to partner with customers to drive innovation. We believe we have the scale and global presence, supported by world-class manufacturing and quality capabilities, to capture these opportunities. We are confident in our capabilities as one of the largest MDO manufacturers, with a long history of successfully integrating companies, driving down costs and growing revenues over the long-term. Ultimately, our strategic vision is to drive shareholder value by enhancing the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

- 27 -

Financial Overview

Net income for the second quarter and first six months of 2021 was $29.4 million, or $0.89 per diluted share, and $51.0 million, or $1.53 per diluted share, respectively, compared to $0.4 million, or $0.01 per diluted share, and $31.5 million, or $0.95 per diluted share for the second quarter and first six months of 2020, respectively. These variances are primarily the result of the following:

  • Sales for the second quarter and first six months of 2021 increased $71.9 million and $33.9 million, respectively, when compared to the same periods in 2020. During the second quarter of 2021 we began to see the demand for many of our products continue to recover from the impacts of the COVID-19 pandemic.
  • Gross profit for the second quarter and first six months of 2021 increased $30.9 million and $18.7 million, respectively, primarily from an increase in sales volume and improved volume leverage.
  • Operating expenses for the second quarter of 2021 increased $0.7 million, compared to the same period in 2020, due to increases in Selling, general and administrative and Research, development and engineering expenses, partially offset by a decrease in Other operating expenses. Operating expenses for the first six months of 2021 decreased $2.0 million, compared to the same period in 2020, due to a decrease in Other operating expenses, partially offset by increases in Selling, general and administrative and Research, development and engineering expenses.
  • Interest expense for the second quarter and first six months of 2021 decreased $1.7 million and $3.6 million, respectively, compared to the same periods in 2020, primarily due to lower outstanding debt balances.
  • During the second quarter and first six months of 2021, we recognized losses on equity investments of $0.7 million and $2.0 million, respectively, compared to a loss of $0.2 million and a gain of $1.7 million, respectively, for the second quarter and first six months of 2020. Gains and losses on equity investments are generally unpredictable in nature.
  • Other (income) loss, net for the second quarter and first six months of 2021 were losses of $0.4 million and $0.1 million, respectively, compared to income of $0.5 million and $1.5 million, respectively, for the second quarter and first six months of 2020, primarily due to fluctuations in foreign currency gains and losses in the respective periods.
  • We recorded provisions for income taxes for the second quarter and first six months of 2021 of $1.3 million and $4.8 million, respectively, compared with an income tax benefit for the second quarter of 2020 of $0.2 million and a provision for income taxes of $5.3 million for the first six months of 2020. The changes in income tax was primarily due to relative changes in pre-tax income and the impact of discrete tax items.

- 28 -

Our Financial Results

The following tables present selected financial information derived from our Condensed Consolidated Financial Statements, contained in Item 1 of this report, for the periods presented (dollars in thousands, except per share).

Medical Sales: Three Months Ended July 2, 2021 July 3, 2020 Change $%
Cardio & Vascular 152,609 $129,084 $23,525 18.2%
Cardiac & Neuromodulation 119,749 71,675 48,074 67.1%
Advanced Surgical, Orthopedics & Portable Medical 29,268 30,625 (1,357) (4.4)%
Total Medical Sales 301,626 231,384 70,242 30.4%
Non-Medical 10,397 8,731 1,666 19.1%
Total sales 312,023 240,115 71,908 29.9%
Cost of sales 223,277 182,252 41,025 22.5%
Gross profit 88,746 57,863 30,883 53.4%
Gross profit as a % of sales 28.4% 24.1%
Operating expenses:
Selling, general and administrative (“SG&A”) 35,379 33,903 1,476 4.4%
SG&A as a % of sales 11.3% 14.1%
Research, development and engineering (“RD&E”) 13,738 12,746 992 7.8%
RD&E as a % of sales 4.4% 5.3%
Other operating expenses 279 2,029 (1,750) (86.2)%
Total operating expenses 49,396 48,678 718 1.5%
Operating income 39,350 9,185 30,165 NM
Operating income as a % of sales 12.6% 3.8%
Interest expense 7,532 9,273 (1,741) (18.8)%
Loss on equity investments 684 205 479 NM
Other (income) loss, net 356 (458) 814 NM
Income before taxes 30,778 165 30,613 NM
Provision (benefit) for income taxes 1,345 (224) 1,569 NM
Effective tax rate 4.4% (135.8)%
Net income $29,433 $389 $29,044 NM
Net income as a % of sales 9.4% 0.2%
Diluted earnings per share $0.89 $0.01 $0.88 NM

NM Calculated amount not meaningful

- 29 -

MANAGEMENT'S DISCUSSION AND ANALYSIS

Medical Sales: Six Months Ended July 2, 2021 July 3, 2020 Change $%
Cardio & Vascular $301,774 $308,289 $(6,515) (2.1)%
Cardiac & Neuromodulation 228,157 179,495 48,662 27.1%
Advanced Surgical, Orthopedics & Portable Medical 54,660 61,862 (7,202) (11.6)%
Total Medical Sales 584,591 549,646 34,945 6.4%
Non-Medical 17,899 18,895 (996) (5.3)%
Total Sales 602,490 568,541 33,949 6.0%
Cost of sales 429,258 413,976 15,282 3.7%
Gross profit 173,232 154,565 18,667 12.1%
Gross profit as a % of sales 28.8% 27.2%
Operating expenses:
SG&A 70,881 70,360 521 0.7%
SG&A as a % of sales 11.8% 12.4%
RD&E 27,199 25,987 1,212 4.7%
RD&E, Net as a % of sales 4.5% 4.6%
Other operating expenses 1,194 4,957 (3,763) (75.9)%
Total operating expenses 99,274 101,304 (2,030) (2.0)%
Operating income 73,958 53,261 20,697 38.9%
Operating margin 12.3% 9.4%
Interest expense 16,064 19,634 (3,570) (18.2)%
(Gain) loss on equity investments, net 2,019 (1,720) 3,739 NM
Other (income) loss, net 119 (1,457) 1,576 NM
Income before taxes 55,756 36,804 18,952 51.5%
Provision for income taxes 4,803 5,315 (512) (9.6)%
Effective tax rate 8.6% 14.4%
Net income $50,953 $31,489 $19,464 61.8%
Net income as a % of sales 8.5% 5.5%
Diluted earnings per share $1.53 $0.95 $0.58 61.1%

NM Calculated amount not meaningful

- 30 -

MANAGEMENT'S DISCUSSION AND ANALYSIS

Product Line Sales

For the second quarter and first six months of 2021, Cardio & Vascular sales increased $23.5 million, or 18%, and decreased $6.5 million, or 2%, respectively, versus the comparable 2020 periods. Cardio & Vascular sales for the second quarter and first six months of 2021 reflect the continued recovery from the negative impact of COVID, with strong increases across all Cardio & Vascular markets, particularly interventional cardiology, electrophysiology, and peripheral vascular. During the second quarter and first six months of 2021, price changes increased Cardio & Vascular sales by $0.2 million and lowered sales by $0.9 million, respectively, in comparison to the 2020 periods. Foreign currency exchange rate fluctuations increased Cardio & Vascular sales for the second quarter and first six months of 2021 by $1.0 million and $2.0 million, respectively, in comparison to the 2020 periods, primarily due to U.S. dollar fluctuations relative to the Euro.

For the second quarter and first six months of 2021, Cardiac & Neuromodulation sales increased $48.1 million, or 67%, and $48.7 million or 27%, respectively, versus the comparable 2020 periods. Cardiac & Neuromodulation sales for the second quarter and first six months of 2021 reflect the continued recovery from the negative impact of COVID, with increases across all Cardiac & Neuromodulation markets. Sales in the cardiac rhythm management market increased high double-digits, and sales in the neuromodulation market doubled. During the second quarter and first six months of 2021, price reductions lowered Cardiac & Neuromodulation sales by $1.9 million and $5.5 million, respectively, in comparison to the 2020 periods. Foreign currency exchange rate fluctuations did not have a material impact on Cardiac & Neuromodulation sales during the second quarter and first six months of 2021 in comparison to the 2020 periods.

In addition to Portable Medical sales, Advanced Surgical, Orthopedic & Portable Medical includes sales to the acquirer of our former AS&O Product Line, under supply agreements entered into as part of the divestiture. For the second quarter and first six months of 2021, Advanced Surgical, Orthopedic & Portable Medical sales decreased $1.4 million, or 4%, and $7.2 million or 12%, respectively, versus the comparable 2020 period as ventilator and patient monitoring components sales declined from pandemic-driven peak demand in 2020. Price reductions and foreign currency exchange rate fluctuations did not have a material impact on Advanced Surgical, Orthopedic & Portable Medical sales during the second quarter and first six months of 2021 in comparison to the 2020 periods.

For the second quarter and first six months of 2021, Non-Medical sales increased $1.7 million, or 19%, and decreased $1.0 million or 5%, respectively, versus the comparable 2020 periods. The sales increase for the second quarter was driven by the emerging recovery of the energy market, which partially offset the negative impact of COVID experienced in the first quarter of 2021. Price reductions and foreign currency exchange rate fluctuations did not have a material impact on Non-Medical sales during the second quarter and first six months of 2021 in comparison to the 2020 periods.

Gross Profit

Changes to gross profit as a percentage of sales (“Gross Margin”) from the prior year were due to the following:

Change From Prior Year Three Months Six Months
Price(a) (0.4)% (0.7)%
Mix(b) 1.3 0.9
Volume Leverage(c) 3.3 1.2
Customer Bankruptcy(d) 0.1 0.2
Total percentage point change to gross profit as a percentage of sales 4.3% 1.6%

(a) Our Gross Margin for the second quarter and first six months of 2021 was negatively impacted by price reductions given to our larger OEM customers in return for long-term volume commitments.

(b) Amounts represent the impact to our Gross Margin attributable to changes in the mix of product sales during the periods.

(c) Our Gross Margin for the second quarter and first six months of 2021 was positively impacted by higher sales volume as our indirect labor and overhead costs are less variable, and in most cases fixed.

(d) In November 2019, one of our customers, Nuvectra Corporation, filed a voluntary Chapter 11 bankruptcy petition (the “Customer Bankruptcy”). During the first quarter of 2020, we incurred costs and recorded charges associated with the Customer Bankruptcy, primarily consisting of charges related to inventory recorded in cost of sales in our Condensed Consolidated Statements of Operations and Comprehensive Income.

- 31 -

SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):

Change From Prior Year Three Months Six Months
Professional fees(a) $(541) $(1,795)
Compensation and benefits(b) 1,666 3,117
Travel and entertainment(c) (99) (1,002)
All other SG&A(d) 450 201
Net increase in SG&A expenses $1,476 $521

(a) Professional fees decreased during the second quarter and first six months of 2021 compared to the prior year periods, primarily due to lower legal costs.

(b) Compensation and benefits increased during the second quarter and first six months of 2021 compared to the prior year periods, primarily due to higher stock-based compensation expense.

(c) Travel and entertainment expenses decreased as a result of the reduction in travel due to the continued impact of the COVID-19 pandemic.

(d) The net increase in all other SG&A for the second quarter and first six months of 2021 compared to the same periods of 2020 is primarily attributable to higher expense for contract services and insurance.

RD&E

RD&E expense for the second quarter and first six months of 2021 were $13.7 million and $27.2 million, respectively, compared to $12.7 million and $26.0 million, respectively, for the second quarter and first six months of 2020. RD&E expenses are influenced by the number and timing of in-process projects and labor hours and other costs associated with these projects. Our research and development initiatives continue to emphasize new product development, product improvements, and the development of new technological platform innovations.

- 32 -

Other Operating Expenses

Other operating expenses (“OOE”) comprise the following (in thousands):

Three Months Ended July 2, 2021 July 3, 2020 Six Months Ended July 2, 2021 July 3, 2020
Operational excellence(a) $191 $443 $845 $1,417
Strategic reorganization and alignment(b) — 138 — 686
Manufacturing alignment to support growth(c) — 60 — 188
Acquisition and integration expenses(d) 26 47 110 403
Other general expenses(e) 62 1,341 239 2,263
Total other operating expenses $279 $2,029 $1,194 $4,957

(a) These projects focus on changing our organizational structure to match product line growth strategies and customer needs, transitioning our manufacturing process into a competitive advantage and standardizing and optimizing our business processes. Expenses for the second quarter and first six months of 2021 and 2020 primarily consist of termination benefits.

(b) These initiatives primarily included aligning resources with our strategic direction, improving profitability to invest in accelerated growth and the expansion of a facility. These actions began in 2017 and were completed during the second quarter of 2020.

(c) These initiatives were designed to reduce costs, increase manufacturing capacity to accommodate growth and improve operating efficiencies by relocating certain manufacturing operations and expanding certain facilities. These actions began in 2017 and were completed during the fourth quarter of 2020.

(d) Amounts include expenses related to the purchase of certain assets and liabilities from business acquisitions. The 2020 amount also includes a $0.5 million adjustment to reduce the fair value of acquisition-related contingent consideration liabilities. See Note 13 “Financial Instruments and Fair Value Measurements” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information related to the fair value measurement of the contingent consideration.

(e) Amounts include expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce future costs and improve efficiencies. The 2020 amount primarily include severance, information technology systems conversion expenses, expenses incurred in connection with the Customer Bankruptcy, and expenses related to the restructuring of certain legal entities of the Company.

Refer to Note 8 “Other Operating Expenses” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information regarding these initiatives.

Interest Expense, Net

Interest expense consists primarily of cash interest and debt related charges, such as amortization of debt issuance costs and original issue discount. For the second quarter and first six months of 2021, interest expense decreased $1.7 million and $3.6 million, respectively, versus the comparable 2020 periods, primarily due to lower amount of debt outstanding. During the second quarter of 2020 we borrowed an additional $160 million of our Revolving Credit Facility to protect against a prolonged pandemic coupled with the risk of financial market illiquidity. The additional borrowing on the Revolving Credit Facility was repaid during the third and fourth quarters of 2020. The weighted average interest rates on outstanding borrowings for the three months and six months ended July 2, 2021 were 3.75% and 3.84%, respectively, compared to 3.60% and 3.94%, respectively, for the comparable periods in 2020.

Debt related charges included in interest expense were $1.1 million and $2.4 million, respectively, during the second quarter and first six months of 2021 compared to $1.0 million and $2.0 million, respectively, during the same periods in 2020. The increases in debt related charges are primarily attributable to write-offs (losses from extinguishment of debt) of deferred issuance costs and unamortized discounts related to prepayments of portions of our Term Loan B facility. We had $0.1 million and $0.4 million, respectively, of losses from extinguishment of debt during the second quarter and first six months of 2021 compared to no losses in the second quarter and first six months of 2020. See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our debt.

- 33 -

As of July 2, 2021, approximately 22% of our principal amount of debt has been converted to fixed-rate borrowings with interest rate swaps, in comparison to approximately 27% as of December 31, 2020. We enter into interest rate swap agreements in order to reduce our exposure to fluctuations in the LIBOR rate. See Note 13 “Financial Instruments and Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our interest rate swap agreements.

(Gain) Loss on Equity Investments

During the second quarter and first six months of 2021, we recognized losses on equity investments of $0.7 million and $2.0 million, respectively. During the second quarter and first six months of 2020, we recognized a loss of $0.2 million and a gain of $1.7 million, respectively. Gains and losses on equity investments are generally unpredictable in nature. The amounts for both 2021 and 2020 relate to our share of equity method investee gains/losses including unrealized appreciation and depreciation of the underlying interests of the investee. As of July 2, 2021 and December 31, 2020, the carrying value of our equity investments was $25.2 million and $27.2 million, respectively. See Note 13 “Financial Instruments and Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further details regarding these investments.

Other (Income) Loss, Net

Other loss, net for the second quarter and first six months of 2021 was $0.4 million and $0.1 million, respectively, compared to other income, net of $0.5 million and $1.5 million, respectively, for the second quarter and first six months of 2020. Other income, net primarily includes gains/losses from the impact of exchange rates on transactions denominated in foreign currencies. Our foreign currency transaction gains/losses are based primarily on fluctuations of the U.S. dollar relative to the Euro, Mexican peso, Uruguayan peso, Malaysian ringgits, or Israeli shekel.

The impact of exchange rates on transactions denominated in foreign currencies included in Other income, net for the second quarter and first six months of 2021 were losses of of $0.4 million and $0.1 million, respectively, compared to gains of $0.5 million and $1.5 million for the second quarter and first six months of 2020, respectively. We continually monitor our foreign currency exposures and seek to take steps to mitigate these risks. However, fluctuations in exchange rates could have a significant impact, positive or negative, on our financial results in the future.

- 34 -

Provision for Income Taxes

We recognized income tax expense of $1.3 million for the second quarter of 2021 on $30.8 million of income before taxes (effective tax rate of 4.4%), compared to an income tax benefit of $0.2 million on $0.2 million of income before taxes (effective tax rate of (135.8)%) for the same period of 2020. The income tax expense for the first six months of 2021 was $4.8 million on $55.8 million of income before taxes (effective tax rate of 8.6%), compared to $5.3 million on income before taxes of $36.8 million (effective tax rate of 14.4%) for the same period of 2020. Income tax expense for the second quarter and first six months of 2021 included $3.8 million and $4.4 million, respectively, of discrete tax benefits consisting principally of $3.5 million of tax benefits related to the reversal of unrecognized tax benefits resulting from effective settlement of tax audits during the second quarter of 2021. There is a potential for volatility in our effective tax rate due to several factors including changes in the mix of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, and settlements with taxing authorities and foreign currency fluctuations. We currently have various tax planning initiatives in place and continuously evaluate planning strategies aimed at reducing our effective tax rate over the long term. This includes strategies to realize deferred tax assets that would otherwise expire unutilized.

Our effective tax rates for 2021 differ from the U.S. federal statutory tax rate of 21% due principally to the net impact of the Company’s earnings outside the U.S., which are generally taxed at rates that differ from the U.S federal rate, the Global Intangible Low-Taxed Income (“GILTI”) tax, the availability of tax credits, and the recognition of discrete tax benefits. The discrete tax benefits for 2021 are predominately related to the reversal of unrecognized tax benefits resulting from the effective settlement of tax audits and excess tax benefits recognized upon vesting of RSUs or exercise of stock options.

Our earnings outside the U.S. are generally taxed at blended rates that are marginally lower than the U.S. federal rate. The GILTI provisions require us to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in our U.S. income tax return. The foreign jurisdictions in which we operate and where our foreign earnings are primarily derived, include Switzerland, Mexico, Uruguay, Malaysia and Ireland. While we are not currently aware of any material trends in these jurisdictions that are likely to impact our current or future tax expense, our future effective tax rates could be adversely affected by earnings being lower than anticipated in countries where we have lower effective tax rates and higher than anticipated in countries where we have higher effective tax rates, or by changes in tax laws or regulations. We regularly assess any significant exposure associated with increases in tax rates in international jurisdictions and adjustments are made as events occur that warrant adjustment to our tax provisions.

Liquidity and Capital Resources

(dollars in thousands)

July 2, 2021 December 31, 2020
Cash and cash equivalents $30,581 $49,206
Working capital $270,116 $256,746
Current ratio 2.65 2.64

Cash and cash equivalents at July 2, 2021 decreased by $18.6 million from December 31, 2020, primarily as a result of debt payments totaling $64.8 million, which include $46.0 million of accelerated payments, purchases of property, plant and equipment of $18.4 million, mostly offset by cash generated by operating activities of $68.8 million.

Working capital increased by $13.4 million from December 31, 2020, primarily from positive working capital fluctuations associated with accounts receivable, contract assets and accrued expenses aggregating to $43.4 million, which were partially offset by fluctuations in cash and cash equivalents and accounts payable aggregating to $36.4 million. During the first six months of 2021, accounts receivable increased mainly from higher sequential sales and contract assets increased due to a contract modification to add existing products and extend the contractual term, while accrued expenses decreased primarily from the payment of accrued incentive compensation. Cash and cash equivalents decreased primarily from accelerated debt payments in the first six months of 2021 while accounts payable increased mainly from the timing of supplier payments and higher sequential inventory purchases.

At July 2, 2021, $10.8 million of our cash and cash equivalents were held by foreign subsidiaries. We intend to limit our distributions from foreign subsidiaries to previously taxed income or current period earnings. If distributions are made utilizing current period earnings, we will record foreign withholding taxes in the period of the distribution.

- 35 -

Summary of Cash Flow

(in thousands)

Cash provided by (used in): Six Months Ended July 2, 2021 July 3, 2020
Operating activities $68,787 $77,954
Investing activities (18,401) (35,954)
Financing activities (69,184) 150,945
Effect of foreign currency exchange rates on cash and cash equivalents 173 (236)
Net change in cash and cash equivalents $(18,625) $192,709

Operating Activities – During the first six months of 2021, we generated cash from operations of $68.8 million, compared to $78.0 million for the first six months of 2020. The decrease of $9.2 million was due to a decrease of $39.0 million in cash flow provided by changes in operating assets and liabilities, partially offset by an increase of $29.9 million in net income adjusted for non-cash items such as depreciation and amortization.

The decrease in cash flow provided by changes in operating assets and liabilities is primarily the result of fluctuations in accounts receivable and accounts payable caused by declining sales in the prior year versus sales growth in the current period. This dynamic caused a significant prior year benefit to operating cash flow from the collection of accounts receivable in a period of declining sales, which resulted from the COVID 19 pandemic. The increase in net income adjusted for non-cash items such as depreciation and amortization is primarily from higher gross profit from sales growth and margin expansion in the current period.

Investing Activities – The $17.6 million decrease in net cash used in investing activities was primarily attributable to decreased purchases of property, plant, and equipment of $8.3 million, intangible assets of $4.1 million, and $5.2 million of cash paid for the acquisition of certain assets and liabilities from InoMec Ltd. in the first quarter of 2020.

Financing Activities – Net cash used in financing activities for first six months of 2021, was $69.2 million compared to $150.9 million provided by financing activities for the first six months of 2020. Financing activities during the first six months of 2021 primarily included debt payments of $64.8 million, compared to net borrowings of $151.3 million for the comparable 2020 period.

During the second quarter of 2020, we borrowed an additional $160 million of our Revolving Credit Facility to protect against a prolonged pandemic coupled with the risk of financial market illiquidity. We subsequently paid down $135 million of the additional borrowing during the third quarter of 2020 and the remainder in the fourth quarter of 2020.

Capital Structure – As of July 2, 2021, our capital structure consists of $669 million of debt, net of deferred debt issuance costs and unamortized discounts, outstanding under our Senior Secured Credit Facilities and 33 million shares of common stock outstanding. We continue to have access to $194.3 million of borrowing capacity under our Revolving Credit Facility, available for normal course of business and letters of credit. We are also authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. As of July 2, 2021, our contractual debt service obligations for the remainder of 2021, consisting of principal and interest on our outstanding debt, are estimated to be approximately $30 million. Actual principal and interest payments may be higher if, for instance, the applicable interest rates on our Senior Secured Credit Facilities increase, we borrow additional amounts on our Revolving Credit Facility, or we pay principal amounts in excess of the required minimums reflected in the contractual debt service obligations above.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and borrowings under our Revolving Credit Facility are sufficient to meet our working capital, debt service and capital expenditure requirements for the next twelve months. If our future financing needs increase, we may need to arrange additional debt or equity financing. We continually evaluate and consider various financing alternatives to enhance or supplement our existing financial resources, including our Senior Secured Credit Facilities. However, we cannot be assured that we will be able to enter into any such arrangements on acceptable terms or at all. In addition, the COVID-19 pandemic, which has caused disruption in the capital markets, could make any such financing more difficult and/or expensive.

- 36 -

Credit Facilities - As of July 2, 2021, we had Senior Secured Credit Facilities that consist of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), which had available borrowing capacity of $194.3 million, (ii) a term loan A facility (the “TLA Facility”) with outstanding principal balance of $211 million, and (iii) a term loan B facility (the “TLB Facility”) with outstanding principal balance of $462 million. The Senior Secured Credit Facilities will mature on October 27, 2022. The Senior Secured Credit Facilities include a mandatory prepayment provision customary for credit facilities of its nature. We are currently in active discussions with existing and potential lending sources and expect to refinance our Senior Secured Credit Facilities prior to October 27, 2021.

The Revolving Credit Facility and TLA Facility contain covenants requiring (A) a maximum total net leverage ratio of 4.75:1.00 subject to a step down to 4.50 to 1.00 for the third fiscal quarter of 2021, and reverting to and remaining at 4.00 to 1.00 beginning with the fourth quarter of 2021 through maturity, and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of 3.0:1.0. Additionally, the total net leverage ratio can be increased by 0.50 for up to four consecutive quarters commencing in any fiscal quarter in which we consummate an Eligible Adjustment Acquisition (as defined in the Amendment) with a $40 million or greater purchase price. As of July 2, 2021, the Company was in compliance with these financial covenants. The TLB Facility does not contain any financial maintenance covenants. As of July 2, 2021, our total net leverage ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 2.7 to 1.0. For the twelve month period ended July 2, 2021, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 8.2 to 1.0.

Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless waived by the lenders. An event of default may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us. As of July 2, 2021, our adjusted EBITDA (as defined in the Senior Secured Credit Facilities) would have to decline by approximately $104 million, or approximately 43%, in order for us to not be in compliance with our financial covenants.

See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further information on the Company’s outstanding debt.

Off-Balance Sheet Arrangements

We do not currently have off balance sheet arrangements that have or are reasonably likely to have a material current or future effect on our Condensed Consolidated Financial Statements.

Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board, Securities and Exchange Commission, or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 1 “Basis of Presentation” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

Contractual Obligations

There have been no significant changes to our contractual obligations during the quarter ended July 2, 2021 as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2020.

Critical Accounting Policies and Estimates

The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.

There have been no significant changes to the critical accounting policies and estimates as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2020.

- 37 -

Market risk

As filed, 607 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Refer to information appearing under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q. Furthermore, a discussion of market risk exposures is included in Part II, Item 7A, Quantitative and Qualitative Disclosure about Market Risk, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Other than the uncertainties resulting from the global pandemic, there have been no material changes in reported market risk since the inclusion of this discussion in the Company’s Annual Report on Form 10-K referenced above.

Controls and procedures

As filed, 1,410 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

a. Evaluation of Disclosure Controls and Procedures

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of July 2, 2021. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of July 2, 2021, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting

During the Company’s most recent fiscal quarter, there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

- 38 -

Risk factors

As filed, 171 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes to the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-07-02. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-04-03 to 2021-07-02$312.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2021-01-01 to 2021-07-02$602.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2021-04-03 to 2021-07-02$223.3mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2021-01-01 to 2021-07-02$429.3mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2021-04-03 to 2021-07-02$88.7mus-gaap:GrossProfit
Gross profit6 months2021-01-01 to 2021-07-02$173.2mus-gaap:GrossProfit
Selling, general and administrative3 months2021-04-03 to 2021-07-02$35.4mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2021-01-01 to 2021-07-02$70.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-04-03 to 2021-07-02$39.4mus-gaap:OperatingIncomeLoss
Operating income6 months2021-01-01 to 2021-07-02$74.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2021-04-03 to 2021-07-02$7.5mus-gaap:InterestExpense
Interest expense6 months2021-01-01 to 2021-07-02$16.1mus-gaap:InterestExpense
Income tax3 months2021-04-03 to 2021-07-02$1.3mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2021-01-01 to 2021-07-02$4.8mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-04-03 to 2021-07-02$29.4mus-gaap:NetIncomeLoss
Net income6 months2021-01-01 to 2021-07-02$51.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-04-03 to 2021-07-02$0.89us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2021-01-01 to 2021-07-02$1.53us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-04-03 to 2021-07-02$0.89us-gaap:EarningsPerShareBasic
Basic EPS6 months2021-01-01 to 2021-07-02$1.55us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-04-03 to 2021-07-0233,254,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2021-01-01 to 2021-07-0233,221,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2021-01-01 to 2021-07-02$68.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2021-01-01 to 2021-07-02$18.4mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-07-02$30.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-07-02$434.2mus-gaap:AssetsCurrent
Total assetsAt period end2021-07-02$2.36bnus-gaap:Assets
Current liabilitiesAt period end2021-07-02$164.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-07-02$1.04bnus-gaap:Liabilities
Long-term debtAt period end2021-07-02$631.2mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2021-07-02$37.5mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2021-07-02$1.31bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001114483-21-000027. Last ingested by Listed: Nov 11, 2026, 00:08 ET. Listed shows no prices and gives no investment advice.